These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 22126291)

  • 1. Epigenetic and epigenomic mechanisms shape sarcoma and other mesenchymal tumor pathogenesis.
    Bennani-Baiti IM
    Epigenomics; 2011 Dec; 3(6):715-32. PubMed ID: 22126291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lysine-specific demethylase 1 is highly expressed in solitary fibrous tumors, synovial sarcomas, rhabdomyosarcomas, desmoplastic small round cell tumors, and malignant peripheral nerve sheath tumors.
    Schildhaus HU; Riegel R; Hartmann W; Steiner S; Wardelmann E; Merkelbach-Bruse S; Tanaka S; Sonobe H; Schüle R; Buettner R; Kirfel J
    Hum Pathol; 2011 Nov; 42(11):1667-75. PubMed ID: 21531005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma.
    Bennani-Baiti IM; Machado I; Llombart-Bosch A; Kovar H
    Hum Pathol; 2012 Aug; 43(8):1300-7. PubMed ID: 22245111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro transformation of mesenchymal stem cells by oncogenic H-rasVal12.
    Shima Y; Okamoto T; Aoyama T; Yasura K; Ishibe T; Nishijo K; Shibata KR; Kohno Y; Fukiage K; Otsuka S; Uejima D; Nakayama T; Nakamura T; Kiyono T; Toguchida J
    Biochem Biophys Res Commun; 2007 Feb; 353(1):60-6. PubMed ID: 17173860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of the FUS-CHOP fusion protein in primary mesenchymal progenitor cells gives rise to a model of myxoid liposarcoma.
    Riggi N; Cironi L; Provero P; Suvà ML; Stehle JC; Baumer K; Guillou L; Stamenkovic I
    Cancer Res; 2006 Jul; 66(14):7016-23. PubMed ID: 16849546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Key roles of histone methyltransferase and demethylase in leukemogenesis.
    Yoshimi A; Kurokawa M
    J Cell Biochem; 2011 Feb; 112(2):415-24. PubMed ID: 21268062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Searching for molecular targets in sarcoma.
    Teicher BA
    Biochem Pharmacol; 2012 Jul; 84(1):1-10. PubMed ID: 22387046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells.
    Riggi N; Cironi L; Provero P; Suvà ML; Kaloulis K; Garcia-Echeverria C; Hoffmann F; Trumpp A; Stamenkovic I
    Cancer Res; 2005 Dec; 65(24):11459-68. PubMed ID: 16357154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
    Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
    J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic modifications in osteogenic differentiation and transformation.
    Thomas D; Kansara M
    J Cell Biochem; 2006 Jul; 98(4):757-69. PubMed ID: 16598744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic cancer therapy: Proof of concept and remaining challenges.
    Mund C; Lyko F
    Bioessays; 2010 Nov; 32(11):949-57. PubMed ID: 21154865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular biology of oncogenic inflammatory processes. I. Non-oncogenic and oncogenic pathogens, intrinsic inflammatory reactions without pathogens, and microRNA/DNA interactions (Review).
    Sinkovics JG
    Int J Oncol; 2012 Feb; 40(2):305-49. PubMed ID: 22076306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The future therapeutic potential of histone demethylases: A critical analysis.
    Natoli G; Testa G; De Santa F
    Curr Opin Drug Discov Devel; 2009 Sep; 12(5):607-15. PubMed ID: 19736620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiR-138 inhibits EZH2 methyltransferase expression and methylation of histone H3 at lysine 27, and affects thermotolerance acquisition.
    Kisliouk T; Yosefi S; Meiri N
    Eur J Neurosci; 2011 Jan; 33(2):224-35. PubMed ID: 21070394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncogenic RAS alters the global and gene-specific histone modification pattern during epithelial-mesenchymal transition in colorectal carcinoma cells.
    Peláez IM; Kalogeropoulou M; Ferraro A; Voulgari A; Pankotai T; Boros I; Pintzas A
    Int J Biochem Cell Biol; 2010 Jun; 42(6):911-20. PubMed ID: 20109579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wnt/beta-catenin signaling in cancer stemness and malignant behavior.
    Fodde R; Brabletz T
    Curr Opin Cell Biol; 2007 Apr; 19(2):150-8. PubMed ID: 17306971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Epigenetic analyses of brain tumor stem cells].
    Natsume A; Kondo Y; Wakabayashi T
    Brain Nerve; 2009 Jul; 61(7):791-8. PubMed ID: 19618856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic remodeling of chromatin architecture: exploring tumor differentiation therapies in mesenchymal stem cells and sarcomas.
    Siddiqi S; Mills J; Matushansky I
    Curr Stem Cell Res Ther; 2010 Mar; 5(1):63-73. PubMed ID: 19807660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deficiency in p53 but not retinoblastoma induces the transformation of mesenchymal stem cells in vitro and initiates leiomyosarcoma in vivo.
    Rubio R; García-Castro J; Gutiérrez-Aranda I; Paramio J; Santos M; Catalina P; Leone PE; Menendez P; Rodríguez R
    Cancer Res; 2010 May; 70(10):4185-94. PubMed ID: 20442289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic mechanisms in glioblastoma multiforme.
    Nagarajan RP; Costello JF
    Semin Cancer Biol; 2009 Jun; 19(3):188-97. PubMed ID: 19429483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.